ערך בספרים למניה: Affimed Therapeutics (AFMD)

The historical valuation of book value per share reflects market expectations for Affimed, where 0.00 becomes the new value for this metric. Stability is ensured by outsourcing antibody production to European CMO partners. Diversification of therapies for various lymphomas via innate immunity activation minimizes risks. The preclinical stage is being accelerated through the implementation of automated high-throughput screening stations.

For the biotech startup Affimed (AFMD), book value per share data on GURU.Markets reflects the actual amount of capital available to shareholders after all liabilities are settled. Since the company generates no commercial revenue, the trend of this metric demonstrates the efficiency of securing venture grants and partnership funds, determining the fundamental stability of the business in the absence of its own sales.